Thian Kheoh
Overview
Explore the profile of Thian Kheoh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
7520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tong X, Patel A, Kim E, Li H, Chen Y, Li S, et al.
Cancer Cell
. 2024 Feb;
42(3):413-428.e7.
PMID: 38402609
KRAS inhibitors (adagrasib and sotorasib) have shown clinical promise in targeting KRAS-mutated lung cancers; however, most patients eventually develop resistance. In lung patients with adenocarcinoma with KRAS and STK11/LKB1 co-mutations,...
2.
Pant S, Wainberg Z, Weekes C, Furqan M, Kasi P, Devoe C, et al.
Nat Med
. 2024 Jan;
30(2):531-542.
PMID: 38195752
Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node...
3.
Paweletz C, Heavey G, Kuang Y, Durlacher E, Kheoh T, Chao R, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3074-3080.
PMID: 37279096
Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here, we report on early ctDNA changes...
4.
Yaeger R, Weiss J, Pelster M, Spira A, Barve M, Ou S, et al.
N Engl J Med
. 2022 Dec;
388(1):44-54.
PMID: 36546659
Background: Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining...
5.
Janne P, Riely G, Gadgeel S, Heist R, Ou S, Pacheco J, et al.
N Engl J Med
. 2022 Jun;
387(2):120-131.
PMID: 35658005
Background: Adagrasib, a KRAS inhibitor, irreversibly and selectively binds KRAS, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b...
6.
Cloughesy T, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, et al.
JAMA Oncol
. 2020 Oct;
6(12):1939-1946.
PMID: 33119048
Importance: New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. Objective: To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca...
7.
Efstathiou E, Davis J, Pisters L, Li W, Wen S, McMullin R, et al.
Eur Urol
. 2019 Jun;
76(4):418-424.
PMID: 31176622
Optimal therapeutic strategy remains an unmet need in localised high-risk prostate cancer (LHRPC). Androgen biosynthesis inhibition in the preoperative setting may improve outcomes. In this single-centre randomised trial, we looked...
8.
Heller G, McCormack R, Kheoh T, Molina A, Smith M, Dreicer R, et al.
J Clin Oncol
. 2018 Jun;
36(22):2354-2356.
PMID: 29894273
No abstract available.
9.
Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder J, Bloomfield S, et al.
Neuro Oncol
. 2018 May;
20(10):1383-1392.
PMID: 29762717
Background: Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of...
10.
Heller G, McCormack R, Kheoh T, Molina A, Smith M, Dreicer R, et al.
J Clin Oncol
. 2017 Dec;
36(6):572-580.
PMID: 29272162
Purpose Measures of response that are clinically meaningful and occur early are an unmet need in metastatic castration-resistant prostate cancer clinical research and practice. We explored, using individual patient data,...